Archemix Initiates Phase 2a For Lead Aptamer Product Candidate ARC1779
Archemix Corp., a privately-held biotechnology company working to develop aptamer-based therapeutics, announced that it has initiated a Phase 2a clinical trial of its novel anti-von Willebrand Factor (VWF) aptamer, ARC1779. The trial is designed to evaluate the safety and efficacy of ARC1779 as a potential first-in-class anti-platelet agent in patients with carotid artery disease undergoing a surgical procedure known as carotid endarterectomy, or CEA.
More: continued here
Filed under: Clinical Trials on April 1st, 2009
You must be logged in to post a comment.